Avalo Therapeutics AVTX
NASDAQ AVTX
$8.51 +1.35 (+18.78%)
As of: Nov 11, 2026 · 3:59 PM EST

Avalo Therapeutics (AVTX) Finished Goods (2017 - 2019)

Updated

Avalo Therapeutics' Finished Goods was $46,705 in Q4 2019, down 90.6% from $497,949 a year earlier.

Analysis

Avalo Therapeutics (AVTX) Finished Goods (2017 - 2019) Analysis & Trends

  • In earlier years, Finished Goods was $497,949 in FY2018 (-11.2%) and $560,499 in FY2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Avalo Therapeutics 386.09 Mn -587.48 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 46,705.00
Dec 31, 2018 497,949.00
Dec 31, 2017 560,499.00
API Access

Avalo Therapeutics Finished Goods API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=finished-goods&ticker=AVTX&period=max&api_key=YOUR_API_KEY